Protective effects of pioglitazone on vascular endothelial cell dysfunction induced by high glucose via inhibition of IKKα/β-NFκB signaling mediated by PPARγ in vitro.
Chunxiang Chen,Shaorong Peng,Fanghui Chen,Lili Liu,Zhouxue Li,Guohua Zeng,Qiren Huang
DOI: https://doi.org/10.1139/cjpp-2016-0574
2017-01-01
Canadian Journal of Physiology and Pharmacology
Abstract:PIO, a synthetic ligand for PPAR gamma, is used clinically to treat T2DM. However, little is known about its protective effects on endothelium and the underlying mechanisms. In this study, we sought to investigate the protective effects of PIO on endothelium and its probable mechanisms: 95% confluent wild type (WT) HUVECs and PPAR gamma(Low)-HUVECs that we first injured with HG (33 mmol.L-1) were first pretreated with 10 mu mol.L-1 of GW9662 for 30 min, and then treated the cells with different concentrations of PIO (5, 10, or 20 mu mol.L-1) for 24 h. Finally, we measured the levels of NO, ET1, TNF alpha, and IL6 in the cell culture supernatant. These cells were then used to determine cell viability, caspase3 activity, the levels of IKK alpha/beta mRNA, IKK alpha/beta, and NF kappa B-p65. Severe dysfunction and activation of IKK alpha/beta-NF kappa B signaling occurred after we exposed HUVECs to HG. Conversely, treatment with PIO significantly attenuated the dysfunction and the activation of IKK alpha/beta-NF kappa B signaling induced by HG in a dose-dependent manner. Moreover, the protective effects of PIO were completely abrogated by GW9662 or down-regulation of PPAR gamma. Taken together, the results indicate that PIO protects HUVECs against the HG-induced dysfunction through the inhibition of IKK alpha/beta-NF kappa B signaling mediated by PPAR gamma.